Brokerages predict that Uniqure NV (NASDAQ:QURE) will report sales of $2.83 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Uniqure’s earnings. The lowest sales estimate is $2.15 million and the highest is $3.50 million. Uniqure reported sales of $9.13 million in the same quarter last year, which indicates a negative year-over-year growth rate of 69%. The business is scheduled to announce its next earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that Uniqure will report full-year sales of $2.83 million for the current financial year, with estimates ranging from $10.50 million to $14.62 million. For the next fiscal year, analysts forecast that the firm will report sales of $13.77 million per share, with estimates ranging from $9.60 million to $20.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Uniqure.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.25. Uniqure had a negative net margin of 338.39% and a negative return on equity of 170.28%.
Several brokerages have recently issued reports on QURE. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a report on Friday, November 10th. ValuEngine upgraded shares of Uniqure from a “sell” rating to a “hold” rating in a report on Monday, January 1st. Evercore ISI began coverage on Uniqure in a report on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 price objective for the company. Oppenheimer restated a “hold” rating on shares of Uniqure in a report on Friday, November 24th. Finally, Leerink Swann increased their price target on Uniqure from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $20.00.
In other news, insider Christian Klemt sold 5,093 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total transaction of $102,522.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Schaffer sold 2,878 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $18.53, for a total transaction of $53,329.34. Following the sale, the director now owns 15,314 shares of the company’s stock, valued at approximately $283,768.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,510 shares of company stock valued at $815,776. 0.73% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in QURE. SG Americas Securities LLC purchased a new position in Uniqure in the 4th quarter valued at approximately $119,000. JPMorgan Chase & Co. grew its stake in Uniqure by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 14,659 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in Uniqure in the 3rd quarter valued at approximately $399,000. Mangrove Partners grew its stake in Uniqure by 167.4% in the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after buying an additional 66,763 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Uniqure in the 4th quarter valued at approximately $1,298,000. Institutional investors and hedge funds own 24.95% of the company’s stock.
Uniqure (NASDAQ:QURE) opened at $18.22 on Friday. The stock has a market cap of $569.18, a price-to-earnings ratio of -6.98 and a beta of 0.57. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64. Uniqure has a 1-year low of $4.72 and a 1-year high of $21.35.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/04/2-83-million-in-sales-expected-for-uniqure-nv-qure-this-quarter.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Get a free copy of the Zacks research report on Uniqure (QURE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.